Mounjaro Generic Name: Tirzepatide vs a Generic Drug

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This page belongs to the PlexusDx Education Hub, where we translate GLP-1 science, weight-management options, and the genetics underneath them into plain language. Explore the full Peptides & GLP-1 library.

The name people are actually asking about

The generic, or nonproprietary, name of Mounjaro is tirzepatide. That answers the terminology question but not the one hiding behind it. A drug's nonproprietary name and a purchasable generic product are two different things. Tirzepatide is simply the scientific name for the active ingredient; there is no FDA-approved generic tirzepatide product on the market as of April 2026.

Why the name exists but the generic does not

Every approved medicine has a nonproprietary name from the day it launches, brand or not. A generic version, by contrast, is a separate product another manufacturer can sell only after patents lapse and the FDA clears it. For tirzepatide, that clearance has not happened. Eli Lilly holds tirzepatide patents running on timelines comparable to semaglutide's, whose composition-of-matter and formulation patents are expected to expire in the United States around 2031 to 2033.

The biosimilar wrinkle

Peptide and biologic drugs do not follow the ordinary small-molecule generic route. The likely future entrant is a biosimilar or follow-on product, which must clear its own clinical demonstration of similarity in pharmacokinetics, pharmacodynamics, and immunogenicity, rather than a simple chemical copy.

What consumers find when they search the generic name

Typing the nonproprietary name into a search bar tends to surface three categories: the name itself with no product behind it, compounded formulations from 503A compounding pharmacies produced during or after the shortage period, and separately branded products, PlexusDx protocols among them, that use the same active ingredient but are formulated and priced on their own terms.

How compounding fits the picture

Through the FDA-declared shortages, semaglutide into late 2024 and tirzepatide into early 2025, 503A compounding pharmacies legally produced compounded versions of these molecules. Both shortages have since been resolved by the FDA, narrowing but not fully closing the compounding window. Compounded tirzepatide remains available through licensed pathways where clinically justified. It is legally and factually distinct from the FDA-approved brand, and it is not a generic.

Timelines and cost routes worth knowing

A true generic or biosimilar cannot arrive until patents expire and the FDA approves one. Expect the tirzepatide patent cliff in the early-to-mid 2030s and semaglutide's slightly ahead of it. In the meantime, cost levers include manufacturer savings cards for eligible insured patients, discount platforms like GoodRx and SingleCare, and the PlexusDx Weight Management Protocols, which publish per-protocol pricing on each page.

The genetic context beneath the label

Names and prices change; your biology does not. Variants in FTO, GLP1R, and MC4R influence appetite regulation and energy balance. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights. It never predicts response to a specific medication; it maps pathway-level context for an informed conversation with a provider.

Brand name versus nonproprietary name, briefly

The confusion behind this search is common because drug naming has two layers. A brand name, Mounjaro, is a trademarked commercial name owned by one company. A nonproprietary name, tirzepatide, is the standardized scientific label that stays constant no matter who eventually makes the molecule. Both exist from a drug's launch, which is why you can know the generic name years before any generic product is legal to sell.

That distinction is more than trivia. When a patent lapses and the FDA later approves a copy, that copy carries the same nonproprietary name, and only then does a purchasable generic exist. Until that point, seeing tirzepatide printed on a label or in an article confirms the ingredient, not availability of a cheaper approved version. Keeping the two layers separate prevents the most common misread that drives these searches.

Frequently Asked Questions

What is the generic name for Mounjaro?

The generic, or nonproprietary, name of Mounjaro is tirzepatide. That is the scientific name of the active ingredient. Knowing it does not mean a generic product exists to purchase, because as of April 2026 there is no FDA-approved generic tirzepatide on the U.S. market for readers to buy.

If tirzepatide is the generic name, why can't I buy a generic?

A nonproprietary name accompanies every drug from launch, while a generic product is a separate item another maker can sell only after patents expire and the FDA approves it. Tirzepatide patents run into the early-to-mid 2030s, and peptide drugs follow the biosimilar pathway rather than ordinary generic approval.

Are compounded versions the same as generic tirzepatide?

No. Compounded tirzepatide is produced by licensed 503A compounding pharmacies and is legally and factually different from the FDA-approved brand product. It is not a generic. Potency and excipients vary by pharmacy, so confirm state licensure and that a prescriber has reviewed clinical suitability before proceeding.

How does the genetic test relate to any of this?

The Precision Peptide Genetic Test does not predict your response to tirzepatide or any medication. It reads pathway-level variants such as FTO, and MC4R that shape baseline appetite and energy-balance biology. That upstream context supports a provider conversation regardless of which product or price route you eventually consider.

Keep reading across the PlexusDx Education Hub. Return to the Peptides & GLP-1 library.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.